Arcellx Inc (ACLX)
53.74
-2.32
(-4.15%)
USD |
NASDAQ |
Jun 25, 16:00
53.74
0.00 (0.00%)
After-Hours: 20:00
Arcellx Research and Development Expense (TTM): 133.24M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 133.24M |
| December 31, 2023 | 133.85M |
| September 30, 2023 | 131.01M |
| June 30, 2023 | 170.68M |
| March 31, 2023 | 164.43M |
| December 31, 2022 | 149.56M |
| Date | Value |
|---|---|
| September 30, 2022 | 137.01M |
| June 30, 2022 | 65.86M |
| March 31, 2022 | 56.42M |
| December 31, 2021 | 46.88M |
| September 30, 2021 | 40.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
40.41M
Minimum
Sep 2021
170.68M
Maximum
Jun 2023
111.76M
Average
133.24M
Median
Mar 2024
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences Inc | 8.222B |
| BridgeBio Pharma Inc | 503.82M |
| Eli Lilly and Co | 9.851B |
| AbbVie Inc | 7.322B |
| Blueprint Medicines Corp | 406.04M |